Overview

A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers

Status:
Completed

Trial end date:
2012-07-01

Target enrollment:

Participant gender:

Summary

The part B of N01362 is to assess the pharmacokinetic profile of Levetiracetam 1500 mg intravenous (iv) infusion during repeated dosing in Chinese healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

UCB Pharma

Treatments:

Etiracetam
Levetiracetam
Piracetam